ClinicalTrials.gg
CompletedNCT02799693Updated Mar 15, 2022

Intramural Needle Ablation for Ventricular Tachycardia

An observational study in Recurrent Ventricular Tachycardia, sponsored by John Sapp. Completed at 1 site in Canada. Per ClinicalTrials.gov, last updated 2022-03-15.

Sponsored by John Sapp · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.

Enrollment
15th of 15
4 · median 1,735
Started
2016
with 2 others
Observational
15 of 54
4 open now
Registered
18th of 54
by date
Lead sponsor
6 of 54
John Sapp

Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 15th largest by enrollment of the 15 observational ones that give a count, is one of 3 that started in 2016, is one of 15 observational ones, and was the 18th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Tachycardia, Ventricular with a site in Canada, or all of them as a file.
02

Study summary

This is a single-arm non-randomized prospective observational cohort study to assess the outcomes of patients undergoing intramural needle catheter ablation of recurrent ventricular tachycardia that has failed antiarrhythmic drug therapy and standard radiofrequency (RF) catheter ablation. Following ablation, patients will be monitored for 6 months. The duration of the study is up to 4 years.

Read the detailed description

This is an observational prospective cohort study of patients undergoing needle catheter ablation. Patients with recurrent sustained or incessant ventricular tachycardia who have recurrent monomorphic ventricular tachycardia that has failed antiarrhythmic drug therapy and prior catheter ablation who are undergoing intramural needle ablation for VT will be offered participation. Data will be collected during the procedure and during follow-up. Patients will be monitored in hospital for complications and during 6 months follow-up.

Data Collection:

Baseline Data: Baseline demographic information and a narrative medical history will be collected on all patients, including documentation of prior cardiac history, and arrhythmia history, as well as prior medications and cardiac procedures.

Procedural data: Details of the procedure including both procedural methods and arrhythmias induced, ablation parameters, needle deployments, recordings and response to procedure.

Followup data: Adverse events will be collected for events which are documented during enrollment and follow-up. During follow-up, hospitalizations will be collected, need for further procedures, implantable defibrillator therapies and procedures will be collected, as well as follow-up echocardiography findings.

03

Conditions studied

  • Recurrent Ventricular Tachycardia

Keywords

  • Catheter Ablation
  • Ventricular Tachycardia
  • Intramural Needle Catheter
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with recurrent ventricular tachycardia who have failed radiofrequency catheter ablation who are undergoing intramural needle catheter ablation procedures.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing catheter ablation using the needle ablation catheter for ventricular arrhythmias.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4 participants (actual)
Patient registry
No

Groups and cohorts

  • Recurrent VT failing RF ablation

    Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.

06

What researchers measure

Primary outcomes

  1. Freedom from hospitalization for recurrent VT during 6 months following ablation

    Control of VT as defined by: freedom from hospitalization for recurrent VT during the 6 months following ablation

    Time frame: 6 months

  2. Absence of serious adverse events attributable to the procedure which occur within 30 days of the ablation procedure

    Absence of all serious adverse events that are potentially procedure related and occur within 30 days of the ablation procedure.

    Time frame: 6 months

Secondary outcomes

  1. Acute Procedural Success

    Termination of at least one clinical or presumptive clinical monomorphic VT by RF ablation or rendering that VT no longer inducible

    Time frame: 6 hours

  2. Acute procedural complications

    Any complications occurring within 24 hours post procedure described as probably or possibly related to the VT catheter ablation procedure

    Time frame: 24 hours

  3. Number of inducible VT morphologies

    Number of VT morphologies induced during catheter ablation

    Time frame: 6 hours

  4. ICD therapy - shocks

    Number of VT events treated with appropriate ICD shocks at 3 months post procedure

    Time frame: 3 months

  5. ICD therapy - shocks

    Number of VT events treated with appropriate ICD shocks at 6 months post procedure

    Time frame: 6 months

  6. ICD therapy - ATP

    Number of VT events treated with antitachycardia pacing (without shock) during 3 months follow-up post-ablation procedure

    Time frame: 3 months

  7. ICD therapy - ATP

    Number of VT events treated with antitachycardia pacing (without shock) during 6 months follow-up post-ablation procedure

    Time frame: 6 months

  8. ICD Therapy

    Number of VT events treated with antitachycardia pacing (with shock) during 3 months follow-up post-ablation procedure

    Time frame: 3 months

  9. ICD Therapy

    Number of VT events treated with antitachycardia pacing (with shock) during 6 months follow-up post-ablation procedure

    Time frame: 6 months

  10. VT storm

    Number of VT storm events during 3 months follow-up

    Time frame: 3 months

  11. VT storm

    Number of VT storm events during 6 months follow-up

    Time frame: 6 months

  12. VT events

    Difference in number of VT events during 3 months prior to and following procedure

    Time frame: 3 months

  13. VT events

    Difference in number of VT events during 6 months prior to and following procedure

    Time frame: 6 months

  14. Recurrent VT

    Time to first recurrent VT

    Time frame: 6 months

  15. Appropriate ATP

    Time to first appropriate ATP

    Time frame: 6 months

  16. Appropriate ICD shock

    Time to first appropriate ICD shock

    Time frame: 6 months

  17. VT Storm

    Time to first VT storm

    Time frame: 6 months

  18. Antiarrhythmic Drug Therapy

    Changes in antiarrhythmic drug therapy post-procedure

    Time frame: 6 months

  19. Total appropriate ICD shocks

    Total number of appropriate ICD shocks during 3 months follow up

    Time frame: 3 months

  20. Total appropriate ICD shocks

    Total number of appropriate ICD shocks during 6 months follow up

    Time frame: 6 months

07

Study locations

1 site
  • QEII Health Sciences Centre
    Halifax, Nova Scotia B3H 3A7, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Apr 2018, 21 months.

Of 69 observational studies under Tachycardia, Ventricular, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 108. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2016
First posted
Jun 15, 2016
StartActual
Jul 2016
Primary completionActual
Apr 5, 2018
CompletionActual
May 30, 2018
Last update
Mar 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02799693
Lead sponsor
John Sapp
Responsible party
John Sapp (MD FRCPC FRHS, Nova Scotia Health Authority) — Sponsor-investigator
First posted
Jun 15, 2016
Start date
Jul 2016
Primary completion
Apr 5, 2018
Completion
May 30, 2018
Last update
Mar 15, 2022

Study contacts

John Sapp, MD FRCPC
principal investigator · Nova Scotia Health Authority

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion